Multi-Specific Antigen Binding Proteins for Fibrin/VEGF and Eye Treatment
Summary
The USPTO published patent application US20260109756A1 on April 23, 2026, disclosing multi-specific antigen binding proteins that bind human fibrin or fibrinogen yC domain and vascular endothelial growth factor (VEGF). Inventors include Kenneth Flanagan, Mathias Rickert, Michael Quigley, and Jeffrey Stavenhagen. The application, originally filed on October 3, 2023 under application number 19117771, covers pharmaceutical compositions and methods of use for treating disorders or conditions of the eye.
“Described herein are multi-specific antigen binding proteins that bind human fibrin or fibrinogen yC domain and vascular endothelial growth factor, and methods of use thereof.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
The USPTO published a patent application (US20260109756A1) disclosing multi-specific antigen binding proteins that bind both human fibrin or fibrinogen yC domain and vascular endothelial growth factor (VEGF). The application covers pharmaceutical compositions and methods of use for treating disorders or conditions of the eye.
Affected parties include pharmaceutical and biotechnology companies developing bispecific or multi-specific antibody therapeutics, particularly those targeting ophthalmic applications. The filing establishes a priority date of October 3, 2023 and may represent prior art for similar therapeutic approaches in development.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MULTI-SPECIFIC ANTIGEN BINDING PROTEINS WHICH BIND HUMAN FIBRIN OR FIBRINOGEN YC DOMAIN AND VASCULAR ENDOTHELIAL GROWTH FACTOR AND METHODS OF USE
Application US20260109756A1 Kind: A1 Apr 23, 2026
Inventors
Kenneth Flanagan, Mathias Rickert, Michael Quigley, Jeffrey Stavenhagen
Abstract
Described herein are multi-specific antigen binding proteins that bind human fibrin or fibrinogen yC domain and vascular endothelial growth factor, and methods of use thereof. In certain aspects, described herein are pharmaceutical compositions comprising the multi-specific antigen binding proteins that bind fibrin or fibrinogen yC domain and vascular endothelial growth factor. In certain aspects, the antibodies and methods described herein are used for treatment of disorders or conditions of the eye.
CPC Classifications
C07K 16/22 A61P 27/02 C07K 16/18 A61K 2039/505 A61K 2039/54 C07K 2317/24 C07K 2317/31 C07K 2317/52 C07K 2317/565 C07K 2317/732 C07K 2317/734 C07K 2317/76 C07K 2317/92 C07K 2317/94
Filing Date
2023-10-03
Application No.
19117771
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.